Wall Street brokerages predict that Retrophin Inc (NASDAQ:RTRX) will announce earnings per share (EPS) of ($0.31) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Retrophin’s earnings, with the highest EPS estimate coming in at $0.02 and the lowest estimate coming in at ($0.64). Retrophin reported earnings per share of $0.01 during the same quarter last year, which would suggest a negative year-over-year growth rate of 3,200%. The firm is expected to report its next quarterly earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that Retrophin will report full-year earnings of $0.10 per share for the current year, with EPS estimates ranging from ($0.77) to $0.96. For the next year, analysts anticipate that the business will post earnings of $0.59 per share, with EPS estimates ranging from $0.33 to $0.84. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Retrophin.
A number of analysts recently commented on the company. ValuEngine raised Retrophin from a “sell” rating to a “hold” rating in a research report on Wednesday, March 7th. BidaskClub raised Retrophin from a “hold” rating to a “buy” rating in a report on Saturday, March 3rd. Finally, Zacks Investment Research raised Retrophin from a “strong sell” rating to a “hold” rating in a report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $44.00.
Shares of Retrophin (RTRX) traded up $0.08 during trading hours on Friday, hitting $25.29. The stock had a trading volume of 74,340 shares, compared to its average volume of 339,807. Retrophin has a 12 month low of $15.55 and a 12 month high of $26.44. The firm has a market cap of $1,004.63, a P/E ratio of -15.11 and a beta of 0.96. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.80 and a quick ratio of 3.74.
Institutional investors and hedge funds have recently modified their holdings of the business. Trexquant Investment LP bought a new stake in Retrophin during the 3rd quarter worth approximately $203,000. Dynamic Technology Lab Private Ltd bought a new stake in Retrophin during the 3rd quarter worth approximately $212,000. Campbell & CO Investment Adviser LLC bought a new stake in Retrophin during the 3rd quarter worth approximately $249,000. Teacher Retirement System of Texas bought a new stake in Retrophin during the 4th quarter worth approximately $256,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in Retrophin during the 3rd quarter worth approximately $349,000.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/zacks-analysts-anticipate-retrophin-inc-rtrx-to-announce-0-31-eps.html.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Get a free copy of the Zacks research report on Retrophin (RTRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.